NCT01011036

Brief Summary

The investigators will use an intradermal capsaicin injection in the forearm to induce a state of localized pain. This localized pain will be measured by different means, and analysed locally and distally by so called quantitative sensory testing. The primary endpoint of measure is the difference in pain perception with and without benzodiazepines/GABA-Agonists around the injection point of capsaicin. The secondary endpoints are to measure pain modulation locally and distally by different quantitative tests as electricity, pressure pain thresholds, and ice water tests. The investigators' hypothesis is that clobazam induces higher pain thresholds as placebo and less sedation than the control medication clonazepam.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
17

participants targeted

Target at below P25 for phase_3 pain

Timeline
Completed

Started Dec 2009

Shorter than P25 for phase_3 pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 6, 2009

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 11, 2009

Completed
20 days until next milestone

Study Start

First participant enrolled

December 1, 2009

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2010

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2010

Completed
Last Updated

August 11, 2010

Status Verified

August 1, 2010

Enrollment Period

4 months

First QC Date

November 6, 2009

Last Update Submit

August 10, 2010

Conditions

Keywords

healthy study subjects, no disease

Outcome Measures

Primary Outcomes (1)

  • area of hyperalgesia on the forearm

    11.2010

Secondary Outcomes (8)

  • Diffuse noxious inhibition control

    11.2010

  • Pressure cuff algometry

    11.2010

  • pressure pain

    11.2010

  • electrical stimulation-temporal summation

    11.2010

  • psychomotor testing

    11.2010

  • +3 more secondary outcomes

Study Arms (3)

1

OTHER
Drug: clobazamDrug: clonazepamDrug: tolterodine

2

OTHER
Drug: clobazamDrug: clonazepamDrug: tolterodine

3

OTHER
Drug: clobazamDrug: clonazepamDrug: tolterodine

Interventions

test substance

123

positive control

123

active placebo

123

Eligibility Criteria

Age18 Years - 55 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • European males
  • years old
  • non smoking status or less than 10 cigarettes per day
  • no disease

You may not qualify if:

  • any medication
  • any drug abuse
  • diseases of any type

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dep of Anesthesiology and Pain Therapy, University Hospital Bern

Bern, 3010, Switzerland

Location

Related Publications (1)

  • Vuilleumier PH, Besson M, Desmeules J, Arendt-Nielsen L, Curatolo M. Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain: a randomized placebo-controlled study. PLoS One. 2013;8(3):e43896. doi: 10.1371/journal.pone.0043896. Epub 2013 Mar 15.

MeSH Terms

Conditions

Pain

Interventions

ClobazamClonazepamTolterodine Tartrate

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

BenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsBenzodiazepinonesPhenylpropanolaminePropanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsPropanolsAminesBenzhydryl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsCresolsPhenols

Study Officials

  • Michele Curatolo, Professor

    University of Bern

    STUDY DIRECTOR
  • Pascal H Vuilleumier, Dr med

    University of Bern

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 6, 2009

First Posted

November 11, 2009

Study Start

December 1, 2009

Primary Completion

April 1, 2010

Study Completion

June 1, 2010

Last Updated

August 11, 2010

Record last verified: 2010-08

Locations